The development of new vaccines against Bacillus anthracis.
about
Anthrax infectionBacillus anthracisAnthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxinIdentification of pathogenic microbial cells and spores by electrochemical detection on a biochipAnthrax vaccination strategiesA NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptideAnthrax: a continuing concern in the era of bioterrorism.Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens.Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challengeAnthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening.Bacillus anthracis: current knowledge in relation to contamination of food.Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis.DNA vaccines against anthrax.Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors.Bacillus anthracis, a story of nature subverted by man.Expression of Bacillus anthracis protective antigen in transgenic chloroplasts of tobacco, a non-food/feed crop.Past, imminent and future human medical countermeasures for anthrax.Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality.The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes.Anthrax lethal toxin and the induction of CD4 T cell immunity.The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.Murine macrophages kill the vegetative form of Bacillus anthracisNon-canonical effects of anthrax toxins on haematopoiesis: implications for vaccine development.Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis.
P2860
Q24616676-06AFCBB0-B604-41AF-A3AA-8BF97EF920B2Q24672893-7E4C35B5-C8E4-4799-A506-2A76945FD688Q24796044-04ECCCF0-1C85-45B7-97D1-3808387C2A20Q24799409-8ADB08C8-2057-424D-9D3C-A7C5C157A609Q28392248-D57E37F9-D7E5-4821-AEC6-FCA495584C02Q28589654-EF0ADBAF-A6ED-4A77-9103-56DCF81FED91Q30232983-2CD10437-B1CF-459B-A33A-3DC5DC31595CQ30783500-8D1DF7E8-C5E7-4A23-BE5E-8A78B3A79D17Q33284583-1E250CEB-9016-4F58-BDB7-987294037C2AQ33505445-0F356F5C-64A3-471C-B872-128155FC1E87Q33883273-A14471ED-6CAD-48A1-BBF4-37498E9B0CF9Q34262140-E0C0FBE0-D0DB-40A5-892F-E67BA2CA393BQ35107590-741D82F0-74EB-480B-9B10-3A9AE3C9A947Q35783791-83719A1F-0601-481E-BC8A-5F9AFD1E4FBAQ35907042-BD14342C-38F4-4307-AF9D-ECE1AE7CF546Q36030835-1A93035D-3DA6-46A8-A2FF-E1B50FFC98F0Q36234189-E67656FB-D6F1-437E-B489-9ACE4F3163B5Q36349402-11849FC8-C44D-4847-8498-C8E1867FBD4FQ36565152-E46C2627-1C0C-4DA6-AF00-7737627BAA6DQ37393185-A52EC675-6285-4107-96DB-D5735EB6616EQ37410339-07777533-E3D7-4B70-8C3B-94502EB9DE54Q38060730-CE922411-9D33-4E33-B7B0-0284E2EC0923Q39205816-F7D41F57-A78A-46E8-8C92-12F726950731Q39394058-B56BECF7-D905-4C3F-8EF0-7A234AB56DB8Q42919729-3220FF8A-04BF-45BA-AE10-B25BB791B222Q44619427-937F5B23-A1D8-4069-BD65-88781A285741
P2860
The development of new vaccines against Bacillus anthracis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The development of new vaccines against Bacillus anthracis.
@ast
The development of new vaccines against Bacillus anthracis.
@en
The development of new vaccines against Bacillus anthracis.
@nl
type
label
The development of new vaccines against Bacillus anthracis.
@ast
The development of new vaccines against Bacillus anthracis.
@en
The development of new vaccines against Bacillus anthracis.
@nl
prefLabel
The development of new vaccines against Bacillus anthracis.
@ast
The development of new vaccines against Bacillus anthracis.
@en
The development of new vaccines against Bacillus anthracis.
@nl
P2860
P1476
The development of new vaccines against Bacillus anthracis.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2672.2001.01498.X
P577
2001-10-01T00:00:00Z